Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BFKB8488A in Overweight/Obese Volunteers
NCT02593331Phase 1Completed
- Sponsor
- Genentech
- Start
- Oct 2015
- Primary completion
- Mar 2017
- Modality
- Bispecific Antibodies, Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of fazpilodemab in obesity and insulin resistance (IR) (3 arms), sponsored by Genentech. Primary endpoint: Percentage of Participants With Adverse Events at 20 weeks. Started Oct 2015; status: completed.
02
Drugs
fazpilodemab
03
Conditions
obesityinsulin resistance (IR)
Beyond the preview
Go deeper on NCT02593331.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02593331.